20.59

2.59% 0.52

Damora Therapeutics Inc (DMRA)

Overview News Price History Discussions Forecast

Damora Therapeutics Inc stock is traded at $20.59, with a volume of 396.16K. It is up +2.59% in the last 24 hours and down -16.30% over the past month. Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Previous Close:

$20.07

Open:

$20.26

24h Volume:

396.16K

Relative Volume:

1.23

Market Cap:

$1.27B

Revenue:

Net Income/Loss:

$-209.84M

P/E Ratio:

-4.5055

EPS:

-4.57

Net Cash Flow:

$-6.73M

1W Performance:

-1.77%

1M Performance:

-16.30%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$19.49

$21.02

1-Week Range:

$18.59

$21.89

52-Week Range:

$16.50

$28.76

Damora Therapeutics Inc Stock (DMRA) Company Profile

Name

Damora Therapeutics Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

(781) 281-9020

Address

221 CRESCENT STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

DMRA's Discussions on Twitter

Compare DMRA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DMRA Damora Therapeutics Inc	20.59	1.24B	0	-209.84M	-6.73M	-4.57
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Initiated	RBC Capital Mkts	Outperform
Mar-25-26	Initiated	Evercore ISI	Outperform
Feb-17-26	Initiated	UBS	Buy
Jan-07-26	Initiated	Leerink Partners	Outperform
Dec-01-25	Initiated	Guggenheim	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Nov-23-20	Initiated	BofA Securities	Buy
Nov-23-20	Initiated	Credit Suisse	Outperform
Nov-23-20	Initiated	SVB Leerink	Outperform

View All

Damora Therapeutics Inc Stock (DMRA) Latest News

Jun 13, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat

Jun 13, 2026

DMRA Q1 2026 Earnings: EPS Misses Estimates as Clinical Costs WeighEPS Guidance Update - newsline.com

Jun 13, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat

Jun 13, 2026

Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat

Jun 13, 2026

Jun 12, 2026

DMRA Reiterates by Wedbush -- Price Target Maintained at $35 - GuruFocus

Jun 12, 2026

Jun 11, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat

Jun 11, 2026

DMRA Initiated Coverage by HC Wainwright & Co. -- Price Target S - GuruFocus

Jun 11, 2026

Jun 09, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat

Jun 09, 2026

Jun 08, 2026

TD Cowen initiates Damora Therapeutics stock rating at Buy - Investing.com UK

Jun 08, 2026

TD Cowen initiates Damora Therapeutics stock rating at Buy By Investing.com - Investing.com India

Jun 08, 2026

Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge - AOL.com

Jun 08, 2026

Jun 01, 2026